Dashboard
Manage Tickers

BMYBRISTOL MYERS SQUIBB CO

NYSE bms.com


$ 44.04 $ -0.08 (-0.18 %)    

Friday, 17-May-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 451.63 $ -0.22 (-0.05 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.76 (0.14 %)
TLT $ 91.40 $ -0.62 (-0.67 %)
GLD $ 223.63 $ 3.63 (1.65 %)
$ 44.03
$ 44.14
$ 44.02 x 400
$ 44.04 x 400
$ 43.73 - $ 44.22
$ 43.33 - $ 64.39
15,411,140
na
89.25B
$ 0.53
nm
TBD
na
na ($ 0.05)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-25-2024 03-31-2024 10-Q
2 02-13-2024 12-31-2023 10-K
3 10-26-2023 09-30-2023 10-Q
4 07-27-2023 06-30-2023 10-Q
5 04-27-2023 03-31-2023 10-Q
6 02-14-2023 12-31-2022 10-K
7 10-26-2022 09-30-2022 10-Q
8 07-27-2022 06-30-2022 10-Q
9 04-29-2022 03-31-2022 10-Q
10 02-09-2022 12-31-2021 10-K
11 10-27-2021 09-30-2021 10-Q
12 07-28-2021 06-30-2021 10-Q
13 04-29-2021 03-31-2021 10-Q
14 02-10-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 02-24-2020 12-31-2019 10-K
19 10-31-2019 09-30-2019 10-Q
20 07-25-2019 06-30-2019 10-Q
21 04-25-2019 03-31-2019 10-Q
22 02-25-2019 12-31-2018 10-K
23 10-25-2018 09-30-2018 10-Q
24 07-26-2018 06-30-2018 10-Q
25 04-26-2018 03-31-2018 10-Q
26 02-13-2018 12-31-2017 10-K
27 10-26-2017 09-30-2017 10-Q
28 07-27-2017 06-30-2017 10-Q
29 04-27-2017 03-31-2017 10-Q
30 02-21-2017 12-31-2016 10-K
31 10-27-2016 09-30-2016 10-Q
32 07-28-2016 06-30-2016 10-Q
33 04-28-2016 03-31-2016 10-Q
34 02-12-2016 12-31-2015 10-K
35 10-27-2015 09-30-2015 10-Q
36 07-23-2015 06-30-2015 10-Q
37 04-28-2015 03-31-2015 10-Q
38 02-13-2015 12-31-2014 10-K
39 10-24-2014 09-30-2014 10-Q
40 07-24-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

abbvie-is-successfully-positioned-to-absorb-humira-biosimilar-erosion--analyst
AbbVie Is 'Successfully Positioned To Abso...
05/17/2024 17:47:16

Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humir...

Core News & Articles
On CNBC, Jason Snipe Announced Bought More...
05/17/2024 17:01:43

fda-approves-expanded-use-of-bristol-myers-squibbs-breyanzi-cancer-cell-therapy-for-previously-treated-follicular-lymphoma
FDA Approves Expanded Use Of Bristol Myers...
05/16/2024 15:56:18

FDA grants accelerated approval for Bristol Myers Squibb's Breyanzi, a CAR T cell therapy, for relapsed or refractory folli...

bristol-myers-squibb-presents-new-4-year-sotyktu-data-demonstrate-durable-response-rates-and-consistent-safety-in-moderate-to-severe-plaque-psoriasis
Bristol Myers Squibb Presents New 4-Year S...
05/16/2024 14:26:57

Following four years of continuous Sotyktu treatment, clinical response was maintained in more than seven out of 10 patients fo...

fda-grants-accelerated-approval-to-bristol-myers-squibbs-lisocabtagene-maraleucel-for-follicular-lymphoma
FDA Grants Accelerated Approval To Bristol...
05/15/2024 20:59:09

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
05/14/2024 17:35:24

bristol-myers-squibb-shares-update-on-phase-3-checkmate--73l-trial-says-trial-did-not-meet-its-primary-endpoint-of-progression-free-survival-in-unresectable-locally-advanced-stage-iii-non-small-cell-lung-cancer
Bristol Myers Squibb Shares Update On Phas...
05/10/2024 20:32:53

Bristol Myers Squibb (NYSE:BMY) today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progressi...

whats-going-on-with-medical-therapeutic-firm-aethlon-medical-on-friday
What's Going On With Medical Therapeutic F...
05/10/2024 14:46:21

Aethlon Medical unveils results in removing extracellular vesicles (EVs) from plasma. Preclinical evidence supports upcoming ph...

wall-streets-most-accurate-analysts-views-on-3-health-care-stocks-with-over-5-dividend-yields
Wall Street's Most Accurate Analysts' View...
05/10/2024 12:01:24

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
05/09/2024 17:35:23

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
05/07/2024 17:35:23

top-4-health-care-stocks-which-could-rescue-your-portfolio-this-month
Top 4 Health Care Stocks Which Could Rescu...
05/07/2024 11:18:46

european-medicines-agency-validates-type-2-variation-application-for-bristol-myers-squibbs-opdivo-nivolumab-plus-yervoy-ipilimumab-for-first-line-treatment-of-microsatellite-instabilityhigh-or-mismatch-repair-deficient-metastatic-colorectal-cancer
European Medicines Agency Validates Type 2...
05/06/2024 11:08:06

fda-bristol-myers-squibbs-application-for-subcutaneous-nivolumab-nivolumab-and-hyaluronidase-with-prescription-drug-user-fee-act-goal-date-of-february-28-2025
FDA Bristol Myers Squibb's Application For...
05/06/2024 11:01:45

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
05/03/2024 17:35:23

Core News & Articles
Editas Medicine Announced A Two-year Exten...
05/01/2024 12:09:34

Under the collaboration, Bristol Myers Squibb has opted into 13 different programs across 11 gene targets to date. Two programs...

a-closer-look-at-bristol-myers-squibbs-options-market-dynamics
A Closer Look at Bristol-Myers Squibb's Op...
04/30/2024 15:31:12

scenic-biotech-enters-into-research-collaboration-with-bristol-myers-squibb
Scenic Biotech Enters Into Research Collab...
04/30/2024 09:03:24

Bristol Myers Squibb gains access to Scenic's Cell-Seq technology platform to unlock the underlying genetic interactions of...

how-is-the-market-feeling-about-bristol-myers-squibb
How Is The Market Feeling About Bristol-My...
04/29/2024 15:45:26

bristol-myers-squibb-and-repertoire-announce-18b-deal-to-reset-immune-system-in-autoimmune-patients
Bristol Myers Squibb and Repertoire Announ...
04/29/2024 10:03:18

Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION